1. Vidaillac C, Chotirmall SH. Pseudomonas aeruginosa in bronchiectasis: infection, inflammation, and therapies. Expert Rev Respir Med. 2021;15(5):649-62.
2. Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature.
2000;406(6799):959-64.
3. Qin S, Xiao W, Zhou C, Pu Q, Deng X, Lan L, et al. Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging
therapeutics. Signal Transduct Target Ther. 2022;7(1):199.
4. Oliver A, Rojo-Molinero E, Arca-Suarez J, Besli Y, Bogaerts P, Canton R, et al. Pseudomonasaeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal
lineages: update from ESGARS-ESCMID/ISARPAE Group. Clin Microbiol Infect. 2024;30(4):469-80.
5. Liao C, Huang X, Wang Q, Yao D, Lu W. Virulence Factors of Pseudomonas Aeruginosa and Antivirulence Strategies to Combat Its Drug Resistance. Front Cell Infect Microbiol. 2022;12:926758.
6. Craig L, Forest KT, Maier B. Type IV pili: dynamics, biophysics and functional consequences. Nat Rev Microbiol. 2019;17(7):429-40.
7. Ozer E, Yaniv K, Chetrit E, Boyarski A, Meijler MM, Berkovich R, et al. An inside look at a biofilm: Pseudomonas aeruginosa flagella biotracking. Sci Adv. 2021;7(24).
8. Hassan R, El-Naggar W, Abd El-Aziz AM, Shaaban M, Kenawy HI, Ali YM. Immunization with outer membrane proteins (OprF and OprI) and flagellin B protects mice from pulmonary
infection with mucoid and nonmucoid Pseudomonas aeruginosa. J Microbiol Immunol Infect. 2018;51(3):312-20.
9. Krell T, Matilla MA. Pseudomonas aeruginosa. Trends Microbiol. 2024;32(2):216-8.
10. Sass G, Miller Conrad LC, Nguyen TH, Stevens DA. The Pseudomonas aeruginosa product pyochelin interferes with Trypanosoma cruzi infection and multiplication in vitro. Trans R Soc
Trop Med Hyg. 2020;114(7):492-8.
11. Pan SY, Shih YL, Huang HH, Li LH, Lin YT, Yang TC. The involvement of PacIRA system of Stenotrophomonas maltophilia in the uptake of Pseudomonas aeruginosa pyochelin and intras-
pecies competition for iron acquisition. J Microbiol Immunol Infect. 2022;55(2):273-81.
12. O’Callaghan R, Caballero A, Tang A, Bierdeman M. Pseudomonas aeruginosa Keratitis: Protease IV and PASP as Corneal Virulence Mediators. Microorganisms. 2019;7(9).
13. Horna G, Ruiz J. Type 3 secretion system as an anti-Pseudomonal target. Microb Pathog. 2021;155:104907.
14. Rojo-Bezares B, Casado C, Ceniceros T, Lopez M, Chichon G, Lozano C, et al. Pseudomonas aeruginosa from river water: antimicrobial resistance, virulence and molecular typing. FEMS
Microbiol Ecol. 2024;100(5).
15. Al-Kadmy IMS, Aziz SN, Hussein NH, El-Shafeiy SN, Hamzah IH, Suhail A, et al. Sequencing analysis and efficient biodiesel production by lipase from Pseudomonas aeruginosa. Mol Biol
Rep. 2024;51(1):323.
16. Dar HH, Epperly MW, Tyurin VA, Amoscato AA, Anthonymuthu TS, Souryavong AB, et al. P. aeruginosa augments irradiation injury via 15-lipoxygenase-catalyzed generation of 15-HpE-
TE-PE and induction of theft-ferroptosis. JCI Insight. 2022;7(4).
17. Rapsinski GJ, Michaels LA, Hill M, Yarrington KD, Haas AL, D’Amico EJ, et al. Pseudomonas aeruginosa senses and responds to epithelial potassium flux via Kdp operon to promote biofilm.
PLoS Pathog. 2024;20(5):e1011453.
18. Botelho J, Grosso F, Peixe L. Antibiotic resistance in Pseudomonas aeruginosa – Mechanisms, epidemiology and evolution. Drug Resist Updat. 2019;44:100640.
19. Maillard JY, Pascoe M. Disinfectants and antiseptics: mechanisms of action and resistance. Nat Rev Microbiol. 2024;22(1):4-17.
20. Sathe N, Beech P, Croft L, Suphioglu C, Kapat A, Athan E. Pseudomonas aeruginosa: Infections and novel approaches to treatment “Knowing the enemy” the threat of Pseudomonas aerugi-
nosa and exploring novel approaches to treatment. Infect Med (Beijing). 2023;2(3):178-94.
21. Elfadadny A, Ragab RF, AlHarbi M, Badshah F, Ibanez-Arancibia E, Farag A, et al. Antimicrobial resistance of Pseudomonas aeruginosa: navigating clinical impacts, current resistance trends,
and innovations in breaking therapies. Front Microbiol. 2024;15:1374466.
22. Caffrey AR, Appaneal HJ, Liao JX, Piehl EC, Lopes V, Puzniak LA. Treatment Heterogeneity in Pseudomonas aeruginosa Pneumonia. Antibiotics (Basel). 2022;11(8).
23. Holmes CL, Anderson MT, Mobley HLT, Bachman MA. Pathogenesis of Gram-Negative Bacteremia. Clin Microbiol Rev. 2021;34(2).
24. Shi Q, Huang C, Xiao T, Wu Z, Xiao Y. A retrospective analysis of Pseudomonas aeruginosa bloodstream infections: prevalence, risk factors, and outcome in carbapenem-susceptible and
-non-susceptible infections. Antimicrob Resist Infect Control. 2019;8:68.
25. Aydin M, Azak E, Bilgin H, Menekse S, Asan A, Mert HTE, et al. Changes in antimicrobial resistance and outcomes of health care-associated infections. Eur J Clin Microbiol Infect Dis.
2021;40(8):1737-42.
26. Amanati A, Sajedianfard S, Khajeh S, Ghasempour S, Mehrangiz S, Nematolahi S, et al. Bloodstream infections in adult patients with malignancy, epidemiology, microbiology, and risk factors
associated with mortality and multi-drug resistance. BMC Infect Dis. 2021;21(1):636.
27. Pena C, Suarez C, Gozalo M, Murillas J, Almirante B, Pomar V, et al. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodst-
ream infections. Antimicrob Agents Chemother. 2012;56(3):1265-72.
28. Turjeman A, von Dach E, Molina J, Franceschini E, Koppel F, Yelin D, et al. Duration of antibiotic treatment for Gram-negative bacteremia – Systematic review and individual participant data
(IPD) meta-analysis. EClinicalMedicine. 2023;55:101750.
29. Tascini C, Antonelli A, Pini M, De Vivo S, Aiezza N, Bernardo M, et al. Infective Endocarditis Associated with Implantable Cardiac Device by Metallo-beta-Lactamase-Producing Pseudomo-
nas aeruginosa, Successfully Treated with Source Control and Cefiderocol Plus Imipenem. Antimicrob Agents Chemother. 2023;67(3):e0131322.
30. Li Y, Roberts JA, Walker MM, Aslan AT, Harris PNA, Sime FB. The global epidemiology of ventilator-associated pneumonia caused by multi-drug resistant Pseudomonas aeruginosa: A
systematic review and meta-analysis. Int J Infect Dis. 2024;139:78-85.
31. Foucrier A, Dessalle T, Tuffet S, Federici L, Dahyot-Fizelier C, Barbier F, et al. Association between combination antibiotic therapy as opposed as monotherapy and outcomes of ICU patients
with Pseudomonas aeruginosa ventilator-associated pneumonia: an ancillary study of the iDIAPASON trial. Crit Care. 2023;27(1):211.
32. Patel P, Whittier S, Frank E. Person-to-person transmission of Pseudomonas pneumonia in the community: documentation by pulsed-field electrophoresis. South Med J. 2002;95(6):653-6.
33. Reynolds D, Kollef M. The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update. Drugs. 2021;81(18):2117-31.
34. Tumbarello M, De Pascale G, Trecarichi EM, Spanu T, Antonicelli F, Maviglia R, et al. Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Intensive Care
Med. 2013;39(4):682-92.
35. Rossi E, La Rosa R, Bartell JA, Marvig RL, Haagensen JAJ, Sommer LM, et al. Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis. Nat Rev Microbiol.
2021;19(5):331-42.
36. Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest. 1998;113(6):1542-
8.
37. Spernovasilis N, Psichogiou M, Poulakou G. Skin manifestations of Pseudomonas aeruginosa infections. Curr Opin Infect Dis. 2021;34(2):72-9.
38. Wu DC, Chan WW, Metelitsa AI, Fiorillo L, Lin AN. Pseudomonas skin infection: clinical features, epidemiology, and management. Am J Clin Dermatol. 2011;12(3):157-69.
39. Vaiman M, Lazarovitch T, Heller L, Lotan G. Ecthyma gangrenosum and ecthyma-like lesions: review article. Eur J Clin Microbiol Infect Dis. 2015;34(4):633-9.
40. Wu J, Chen N, Grau E, Johnson L, Liu Y, Li C, et al. Short chain fatty acids inhibit corneal inflammatory responses to TLR ligands via the ocular G-protein coupled receptor 43. Ocul Surf.
2024;32:48-57.
41. Tribin FE, Lieux C, Maestre-Mesa J, Durkee H, Krishna K, Chou B, et al. Clinical Features and Treatment Outcomes of Carbapenem-Resistant Pseudomonas aeruginosa Keratitis. JAMA
Ophthalmol. 2024;142(5):407-15.
42. Chuang CH, Wang YH, Chang HJ, Chen HL, Huang YC, Lin TY, et al. Shanghai fever: a distinct Pseudomonas aeruginosa enteric disease. Gut. 2014;63(5):736-43.
43. Ross JJ, Shamsuddin H. Sternoclavicular septic arthritis: review of 180 cases. Medicine (Baltimore). 2004;83(3):139-48.
44. Huang L, Wu C, Gao H, Xu C, Dai M, Huang L, et al. Bacterial Multidrug Efflux Pumps at the Frontline of Antimicrobial Resistance: An Overview. Antibiotics (Basel). 2022;11(4).
45. Li H, Luo YF, Williams BJ, Blackwell TS, Xie CM. Structure and function of OprD protein in Pseudomonas aeruginosa: from antibiotic resistance to novel therapies. Int J Med Microbiol.
2012;302(2):63-8.
46. Vatansever C, Menekse S, Dogan O, Gucer LS, Ozer B, Ergonul O, et al. Co-existence of OXA-48 and NDM-1 in colistin resistant Pseudomonas aeruginosa ST235. Emerg Microbes Infect.
2020;9(1):152-4.